FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, namely to a genetically engineered T-cell expressing on its surface a chimeric antigen receptor (CAR) specific for CD22 (CAR22), and a chimeric antigen receptor specific for CD20 (CAR20), a method for production thereof, as well as a pharmaceutical composition containing it. Also disclosed is an isolated polynucleotide encoding CAR20 and CAR22, as well as a vector containing said polynucleotide.
EFFECT: invention is effective for treating cancer associated with CD22 expression, for treating cancer associated with CD20 expression, as well as for treating cancer associated with CD20 and CD22 expression.
17 cl, 8 dwg, 7 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| CELL | 2015 |
|
RU2768019C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
